CRISPR Therapeutics
(NASDAQ) CRSP
CRISPR Therapeutics Financials at a Glance
Market Cap
$5.59B
Revenue (TTM)
$3.51M
Net Income (TTM)
$581.60M
EPS (TTM)
$-6.51
P/E Ratio
-8.90
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$57.98
Volume
61,551
Open
$57.74
Price
$57.98
Volume
61,551
Open
$57.74
Previous Close
$57.98
Daily Range
$57.10 - $59.13
52-Week Range
$33.03 - $78.48
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$57.98
Volume
61,551
Open
$57.74
Previous Close
$57.98
Daily Range
$57.10 - $59.13
52-Week Range
$33.03 - $78.48
CRSP News
Best Biotech ETFs to Buy in 2026
CRSP: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout CRISPR Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
393
CEO
Samarth Kulkarni, PhD
Website
www.crisprtx.comHeadquarters
Zug, 6300, CH
CRSP Financials
Key Financial Metrics (TTM)
Gross Margin
-65%
Operating Margin
-162%
Net Income Margin
-166%
Return on Equity
-30%
Return on Capital
-27%
Return on Assets
-26%
Earnings Yield
-11.24%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.59B
Shares Outstanding
96.39M
Volume
61.55K
Short Interest
0.00%
Avg. Volume
1.89M
Financials (TTM)
Gross Profit
$229.45M
Operating Income
$568.32M
EBITDA
$548.84M
Operating Cash Flow
$345.01M
Capital Expenditure
$914.00K
Free Cash Flow
$345.93M
Cash & ST Invst.
$1.98B
Total Debt
$394.91M
CRISPR Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$864.00K
-97.5%
Gross Profit
$58.50M
-267.1%
Gross Margin
-67.71%
N/A
Market Cap
$5.59B
N/A
Market Cap/Employee
$14.22M
N/A
Employees
393
N/A
Net Income
$130.61M
-250.1%
EBITDA
$149.10M
-149.6%
Quarterly Fundamentals
Net Cash
$1.58B
-5.9%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$376.34M
+82.3%
Short Term Debt
$18.58M
+7.5%
Return on Assets
-25.67%
N/A
Return on Invested Capital
-26.86%
N/A
Free Cash Flow
$93.07M
-85.1%
Operating Cash Flow
$92.55M
-85.0%